BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29869738)

  • 1. Rethinking medulloblastoma from a targeted therapeutics perspective.
    Hashimoto Y; Penas-Prado M; Zhou S; Wei J; Khatua S; Hodges TR; Sanai N; Xiu J; Gatalica Z; Kim L; Kesari S; Rao G; Spetzler D; Heimberger A
    J Neurooncol; 2018 Sep; 139(3):713-720. PubMed ID: 29869738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytogenetic evaluation of isochromosome 17q in posterior fossa tumors of children and correlation with clinical outcome in medulloblastoma. Detection of a novel chromosomal abnormality.
    DeChiara C; Borghese A; Fiorillo A; Genesio R; Conti A; D'Amore R; Pettinato G; Varone A; Maggi G
    Childs Nerv Syst; 2002 Aug; 18(8):380-4. PubMed ID: 12192498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
    Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
    J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
    Gajjar A; Robinson GW; Smith KS; Lin T; Merchant TE; Chintagumpala M; Mahajan A; Su J; Bouffet E; Bartels U; Schechter T; Hassall T; Robertson T; Nicholls W; Gururangan S; Schroeder K; Sullivan M; Wheeler G; Hansford JR; Kellie SJ; McCowage G; Cohn R; Fisher MJ; Krasin MJ; Stewart CF; Broniscer A; Buchhalter I; Tatevossian RG; Orr BA; Neale G; Klimo P; Boop F; Srinivasan A; Pfister SM; Gilbertson RJ; Onar-Thomas A; Ellison DW; Northcott PA
    J Clin Oncol; 2021 Mar; 39(7):822-835. PubMed ID: 33405951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas.
    Sandén E; Dyberg C; Krona C; Visse E; Carén H; Northcott PA; Kool M; Ståhl N; Persson A; Englund E; Johnsen JI; Siesjö P; Darabi A
    J Neurooncol; 2015 May; 123(1):1-13. PubMed ID: 25820321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular studies in pediatric medulloblastomas.
    Ramachandran C; Khatib Z; Escalon E; Fonseca HB; Jhabvala P; Medina LS; D'Souza B; Ragheb J; Morrison G; Melnick SJ
    Brain Tumor Pathol; 2002; 19(1):15-22. PubMed ID: 12455884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical detection of ALK protein identifies APC mutated medulloblastoma and differentiates the WNT-activated medulloblastoma from other types of posterior fossa childhood tumors.
    Łastowska M; Trubicka J; Karkucińska-Więckowska A; Kaleta M; Tarasińska M; Perek-Polnik M; Sobocińska AA; Dembowska-Bagińska B; Grajkowska W; Matyja E
    Brain Tumor Pathol; 2019 Jan; 36(1):1-6. PubMed ID: 30523493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
    Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
    J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extraneuraxial metastases in medulloblastoma: is histology and molecular biology important?
    Gupta T; Dasgupta A; Epari S; Shirsat N; Chinnaswamy G; Jalali R
    J Neurooncol; 2017 Nov; 135(2):419-421. PubMed ID: 28755322
    [No Abstract]   [Full Text] [Related]  

  • 10. EZH2-regulated DAB2IP is a medulloblastoma tumor suppressor and a positive marker for survival.
    Smits M; van Rijn S; Hulleman E; Biesmans D; van Vuurden DG; Kool M; Haberler C; Aronica E; Vandertop WP; Noske DP; Würdinger T
    Clin Cancer Res; 2012 Aug; 18(15):4048-58. PubMed ID: 22696229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpressed TP73 induces apoptosis in medulloblastoma.
    Castellino RC; De Bortoli M; Lin LL; Skapura DG; Rajan JA; Adesina AM; Perlaky L; Irwin MS; Kim JY
    BMC Cancer; 2007 Jul; 7():127. PubMed ID: 17626635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.
    Thompson MC; Fuller C; Hogg TL; Dalton J; Finkelstein D; Lau CC; Chintagumpala M; Adesina A; Ashley DM; Kellie SJ; Taylor MD; Curran T; Gajjar A; Gilbertson RJ
    J Clin Oncol; 2006 Apr; 24(12):1924-31. PubMed ID: 16567768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.
    Everson RG; Hashimoto Y; Freeman JL; Hodges TR; Huse J; Zhou S; Xiu J; Spetzler D; Sanai N; Kim L; Kesari S; Brenner A; De Monte F; Heimberger A; Raza SM
    J Neurooncol; 2018 Sep; 139(2):469-478. PubMed ID: 29846894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features.
    Leonard JR; Cai DX; Rivet DJ; Kaufman BA; Park TS; Levy BK; Perry A
    J Neurosurg; 2001 Jul; 95(1):82-8. PubMed ID: 11453402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients.
    Priller M; Pöschl J; Abrão L; von Bueren AO; Cho YJ; Rutkowski S; Kretzschmar HA; Schüller U
    Clin Cancer Res; 2011 Nov; 17(21):6791-801. PubMed ID: 21918172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA content and other prognostic features in childhood medulloblastoma. Proposal of a scoring system.
    Schofield DE; Yunis EJ; Geyer JR; Albright AL; Berger MS; Taylor SR
    Cancer; 1992 Mar; 69(5):1307-14. PubMed ID: 1739930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulation of genomic aberrations during clinical progression of medulloblastoma.
    Korshunov A; Benner A; Remke M; Lichter P; von Deimling A; Pfister S
    Acta Neuropathol; 2008 Oct; 116(4):383-90. PubMed ID: 18704466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supratentorial neurometabolic alterations in pediatric survivors of posterior fossa tumors.
    Rueckriegel SM; Driever PH; Bruhn H
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1135-41. PubMed ID: 21658852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth.
    Binning MJ; Niazi T; Pedone CA; Lal B; Eberhart CG; Kim KJ; Laterra J; Fults DW
    Cancer Res; 2008 Oct; 68(19):7838-45. PubMed ID: 18829539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [From cytogenetics to cytogenomics of brain tumors: 1. Medulloblastoma].
    Vagner-Capodano AM; Zattara-Cannoni H; Quilichini B; Giocanti G;
    Bull Cancer; 2003 Apr; 90(4):315-8. PubMed ID: 12801814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.